Search

Your search keyword '"Vilà M"' showing total 547 results

Search Constraints

Start Over You searched for: Author "Vilà M" Remove constraint Author: "Vilà M"
547 results on '"Vilà M"'

Search Results

1. The Near Infrared Imager and Slitless Spectrograph for the James Webb Space Telescope -- III. Single Object Slitless Spectroscopy

2. The Near Infrared Imager and Slitless Spectrograph for the James Webb Space Telescope -- I. Instrument Overview and in-Flight Performance

3. The Near Infrared Imager and Slitless Spectrograph for the James Webb Space Telescope -- IV. Aperture Masking Interferometry

7. Carbon nanotube synthesis and spinning as macroscopic fibers assisted by the ceramic reactor tube

10. Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study

11. The Internationalization in the Learning of the Accounting Profession: Use of the Kahoot as a Teaching Tool for Learning

18. A scenario-guided strategy for the future management of biological invasions

19. A scenario-guided strategy for the future management of biological invasions

20. Early-season mass-flowering crop cover dilutes wild bee abundance and species richness in temperate regions : A quantitative synthesis

21. A scenario-guided strategy for the future management of biological invasions

27. Early‐season mass‐flowering crop cover dilutes wild bee abundance and species richness in temperate regions: A quantitative synthesis

28. Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types

29. Study of the Convergence in Automatic Generation of Instance Level Constraints

32. A review of the combination among global change factors in forests, shrublands and pastures of the Mediterranean Region: Beyond drought effects

37. European scenarios for future biological invasions

46. 155TiP A randomised phase II trial of neoadjuvant multi-agent chemotherapy (CHT) OR patritumab deruxtecan (HER3-DXd; U3-1402) +/- endocrine therapy (ET) for high-risk hormone receptor-positive (HR+/HER2-) early breast cancer (EBC): SOLTI-2103 VALENTINE trial

47. 124O Patritumab deruxtecan (HER3-DXd) in hormonal receptor-positive/HER2-negative (HR+/HER2-) and triple-negative breast cancer (TNBC): Results of part B of SOLTI TOT-HER3 window of opportunity trial

48. 240P Effect of dose intensity (DI) of palbociclib (PAB) and initial body weight dosage (BWD) on progression free survival (PFS): A real-world data analysis in patients with hormone-receptor (HR) positive HER2 negative metastatic breast cancer (MBC)

50. 3MO HER2 expression and early response to patritumab deruxtecan (HER3-DXd) in early-stage hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC): A correlative analysis from SOLTI-TOT-HER3 trial

Catalog

Books, media, physical & digital resources